Can I Still Apply for the Suboxone Lawsuit in 2026?

Quick Answer
– What it is: A federal mass tort lawsuit against Indivior PLC alleging that Suboxone sublingual film causes severe dental injuries including tooth decay, erosion, and tooth loss, consolidated in MDL 3092 before Judge David A. Ruiz in the Northern District of Ohio.
– Who qualifies: Adults who used Suboxone film (not tablets) and suffered documented dental injuries, with no prior history of comparable dental disease attributable to another cause.
– What it may be worth: Early projections and attorney analyses suggest individual awards ranging from $10,000 to $150,000+, depending on severity of dental injury and documented treatment costs, though no global settlement figure has been publicly confirmed as of 2026.

Case Snapshot

Tens of thousands of Americans used Suboxone film as part of opioid use disorder treatment, then watched their teeth deteriorate in ways their doctors never warned them about. The question in 2026 is direct: can you still apply for the Suboxone lawsuit, and does your situation meet the threshold?

The answer, for most eligible claimants, is yes. MDL 3092 remains active before Judge David A. Ruiz in the Northern District of Ohio. New plaintiffs continued joining the litigation through 2025, and mass torts of this scale typically absorb new claims for years before global resolution.

A related guide: Aspen Dental Lawsuit 2026: Claims, Payouts & Class Action

The filing window is not infinite. Statute of limitations rules, state-specific tolling doctrines, and potential case management orders from the court all create real deadlines. Waiting carries documented legal risk.

What follows is a precise account of where MDL 3092 stands, who qualifies, what documentary evidence is required, and what the parallel antitrust track means for a different category of claimants.

Can I Still Apply for the Suboxone Lawsuit?

Yes, you can still apply for the Suboxone lawsuit as of 2026. MDL 3092 is active, no global settlement has been announced, and the court has not issued a bar date that would formally cut off new filings across the MDL.

However, "still open" does not mean "open indefinitely." Mass tort MDLs can move toward resolution quickly once bellwether trials produce outcomes. Attorneys who handle these cases consistently advise that waiting until the litigation approaches settlement narrows your options considerably.

The relevant deadline framework is state-specific. Each plaintiff's claim is governed by the personal injury statute of limitations in the state where they lived when the injury occurred, or where they received treatment. Those windows range from one year to six years depending on the state.

Key 2026 Status Points:

• MDL 3092 remains open for new plaintiff filings
• Bellwether trial scheduling is ongoing before Judge Ruiz
• No global resolution or settlement fund has been publicly confirmed
• FDA's January 2022 dental safety communication anchors the defendant's notice timeline

*Attorneys handling these claims point to the FDA's 2022 warning as a significant marker, because defendants will argue that claimants who filed after becoming aware of the risk may face discovery accrual date disputes.*

Is the Suboxone Lawsuit Still Active?

The Suboxone lawsuit is still active as of 2026. MDL 3092 was formally centralized by the U.S. Judicial Panel on Multidistrict Litigation in February 2023, transferring related federal cases to the Northern District of Ohio.

Since centralization, the litigation has moved through coordinated discovery. Indivior PLC and co-defendant Aquestive Therapeutics have engaged in document production and deposition scheduling under the court's management orders.

No final settlement or verdict has been entered. The case is not concluded, and plaintiffs are not barred from joining the MDL through appropriate counsel.

*Attorneys handling these claims point to the bellwether trial process as the clearest signal of where the litigation is heading. Outcomes from those initial trials typically drive defendants toward global resolution discussions.*

Suboxone MDL 3092 Update 2026

MDL 3092, formally styled as *In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation*, entered a critical phase in 2026. The centralization before Judge David A. Ruiz in the Northern District of Ohio brought hundreds of federal cases under unified case management.

Judge Ruiz has been managing coordinated discovery across plaintiff and defense expert witnesses, internal company documents related to Indivior's knowledge of dental risk, and the adequacy of Suboxone's warnings. This is the phase where the factual record that will drive any eventual resolution gets built.

The MDL model works in stages. Early consolidation handles shared discovery. Bellwether cases then go to trial to test how juries respond to the core liability arguments. Those outcomes, in turn, create settlement pressure.

What Has Happened in MDL 3092 Since 2023:

• Thousands of individual cases transferred into the MDL
• Indivior and Aquestive have both been named as defendants
• Plaintiff Steering Committee established to coordinate strategy
• Discovery orders covering internal Indivior documents on dental injury awareness
• Expert witness phases underway as of 2025 and continuing into 2026

*Attorneys handling these claims point to Indivior's internal communications as the most contested area of discovery, since the company's awareness of the sublingual film's pH and its effect on enamel predates the FDA's 2022 warning.*

Litigation Watch: MDL 3092 is in active litigation before Judge David A. Ruiz, and no global settlement has been announced, meaning the window to file remains open but the litigation clock is advancing.

Who Qualifies for the Suboxone Lawsuit?

The Suboxone lawsuit covers individuals who used the sublingual film formulation of Suboxone and suffered documented dental injuries as a direct result. Qualification is not automatic, and several threshold criteria apply.

Eligibility centers on the film product specifically, the nature and severity of the dental harm, and the absence of a competing explanation for the dental damage. An existing history of significant dental disease before Suboxone use does not automatically disqualify a claimant, but it becomes a factual battleground.

Core Eligibility Criteria:

*Attorneys handling these claims point to the importance of obtaining all dental records from before, during, and after Suboxone use, because the defense will attempt to attribute damage to pre-existing conditions or other factors.*

Suboxone Lawsuit Eligibility 2026

Eligibility requirements in 2026 follow the same product liability framework that has governed MDL 3092 since centralization. The question is whether you used the film, whether you have dental injury, and whether the timeline supports causation.

The FDA issued its dental safety communication in January 2022. That notice stated that buprenorphine medicines dissolved in the mouth can cause dental problems including tooth decay, cavities, oral infections, and in some cases tooth loss.

Claimants who used Suboxone film before 2022 and developed dental problems during that period have a strong causation timeline. The company's failure to warn prior to the FDA action is central to plaintiff arguments.

Eligibility Quick Reference for 2026:

• Used Suboxone film at any point during your treatment
• Experienced dental decay, erosion, tooth fracture, or tooth loss
• Dental problems arose during or after your Suboxone film use period
• You have, or can obtain, prescription records and dental records
• Your injury occurred within your state's personal injury statute of limitations, or a tolling argument applies

*Attorneys handling these claims point to the FDA's 2022 notice as double-edged: it confirms that the risk is real and that Indivior failed to warn patients adequately for years prior.*

Suboxone Film vs. Tablet Lawsuit Difference

The Suboxone film and the Suboxone tablet are not equivalent for purposes of this lawsuit. Only the sublingual film formulation is at the center of MDL 3092.

The distinction is pharmacological and mechanical. The film dissolves directly against oral tissue for extended contact time. That prolonged contact with acidic content in the sublingual film is the alleged mechanism of enamel erosion and decay.

Suboxone tablets do not share the same dissolution profile or extended oral contact. They were also discontinued by Indivior in 2012, a move that plaintiffs in the antitrust litigation argued was made to force patients onto the more profitable film while blocking generic competition. That allegation belongs to the separate antitrust track.

*Attorneys handling these claims point out that a patient who used both formulations at different times should still discuss eligibility with counsel, since the film use period is what matters for dental injury claims.*

Litigation Watch: Only the sublingual film formulation is at issue in MDL 3092's dental injury track, making the product-specific history of each claimant the threshold eligibility question.

What Dental Injuries Qualify for the Suboxone Lawsuit?

Qualifying dental injuries are those caused or materially worsened by the acidic properties of the Suboxone sublingual film during the dissolution process. The FDA's January 2022 safety communication identified specific injury categories that now anchor plaintiff claims.

Severity matters for both eligibility and compensation tiers. A claimant with minor sensitivity is in a different evidentiary position than one who lost multiple teeth or required full dental reconstruction.

Dental Injuries Recognized in the Suboxone Litigation:

*Attorneys handling these claims point to the need for a complete dental timeline: records from before Suboxone use, during, and after. The comparison between pre- and post-treatment dental health is the foundation of the causation argument.*

Suboxone Film Dental Injury Claims

Suboxone film dental injury claims are product liability actions alleging that Indivior and Aquestive Therapeutics designed and marketed a drug delivery system that caused foreseeable, documented harm to patients' teeth while failing to disclose that risk.

The legal theory is failure to warn combined with design defect. Plaintiffs argue that Indivior knew, or should have known, that prolonged sublingual exposure to the film's acidic components would damage enamel and cause decay. The company did not add a dental warning to the product label until the FDA required it in 2022.

That is a years-long gap between internal awareness and public disclosure that plaintiff attorneys have made central to their case strategy.

Core Documents Claimants Should Gather:

• Prescription records showing Suboxone film use and duration
• Pharmacy fill records confirming the film formulation
• Dental records predating Suboxone use (baseline dental health)
• Dental records during and after Suboxone use showing injury onset
• Receipts or insurance records for dental treatment costs
• Physician or treatment provider records confirming Suboxone use for opioid use disorder

*Attorneys handling these claims point to the prescription duration as a key variable, because longer use periods correlate with more severe injury and often produce stronger causation timelines.*

Litigation Watch: Plaintiff claims center on failure to warn and design defect, with the FDA's 2022 labeling change serving as a public acknowledgment that the dental risk was real and previously undisclosed.

This is also helpful: Drake UMG Lawsuit 2026: Claims, Court Status, Outcome

Suboxone Lawsuit Settlement Amount 2026

No global Suboxone lawsuit settlement amount has been publicly announced as of 2026. The litigation remains in the pre-trial phase, and mass torts of this scale rarely produce confirmed settlement figures until bellwether trial outcomes create a pricing framework both sides can use.

What attorneys and legal analysts project is based on analogous pharmaceutical product liability MDLs and the severity distribution of injuries across the plaintiff pool. Those projections vary significantly by injury tier.

Projected Settlement Ranges by Injury Severity:

These figures are attorney and analyst projections. Actual awards depend on bellwether trial outcomes, negotiated settlement structures, and individual case-specific evidence.

*Attorneys handling these claims point to dental reconstruction costs, pain and suffering, and documented economic loss from missed work due to dental procedures as the three pillars driving individual award calculations.*

Suboxone Lawsuit Payout Per Person

The payout per person in the Suboxone lawsuit will not be uniform. Mass tort MDL settlements distribute differently than class actions, where every member receives approximately the same amount.

In a mass tort like MDL 3092, each plaintiff's recovery is individually assessed against a point or tier system negotiated as part of any eventual settlement agreement. Factors that drive individual payouts higher include documented injury severity, out-of-pocket dental costs, lost wages, and the clarity of the causation timeline.

Factors That Increase Individual Payout:

• Extended duration of Suboxone film use
• Complete dental records showing clear before-and-after comparison
• High out-of-pocket dental treatment expenses
• Multiple teeth affected or lost
• Documented pain, infection, or oral surgery required
• Strong prescription record confirming the film formulation was used

Factors That Can Reduce Payout:

• Pre-existing dental disease with similar characteristics
• Gaps in dental records making causation harder to establish
• Short duration of Suboxone film use
• Tobacco use or other confounding factors the defense will raise
• Late filing relative to the discovery of injury

*Attorneys handling these claims point to the importance of preserving every dental bill and explanation of benefits document, since economic damages are among the most cleanly documented and hardest for the defense to contest.*

Suboxone Tooth Decay Lawsuit Filing Deadline

There is no single universal filing deadline for the Suboxone tooth decay lawsuit. The applicable deadline for each claimant is determined by the statute of limitations in their home state and when they knew, or reasonably should have known, that their dental injuries were caused by Suboxone film.

The FDA's January 2022 dental safety communication is a pivotal date. Courts may treat that date as constructive notice for some claimants, meaning the limitations clock in some states could potentially start running from early 2022 for those who had already experienced dental symptoms.

State Statute of Limitations Reference (Personal Injury):

Tolling doctrines, the discovery rule, and MDL-specific tolling agreements with defendants can extend these windows. An attorney must evaluate the specific facts of each claim.

*Attorneys handling these claims point to the discovery rule as critical: in states where it applies robustly, the limitations clock starts when you discovered, or should have discovered, that Suboxone caused the harm, not when the harm first appeared.*

Litigation Watch: State-specific statutes of limitations and the FDA's January 2022 dental warning together create a deadline framework that varies by claimant, making early consultation with a mass tort attorney the most legally protective step available.

Suboxone Lawsuit Statute of Limitations

The statute of limitations for the Suboxone lawsuit is the single most time-sensitive legal issue for new claimants in 2026. It is not a single date. It is a state-by-state calculation that depends on when injury was discovered and what tolling protections may apply.

The discovery rule is the primary tool that may protect claimants who used Suboxone film years ago. Under the discovery rule, the limitations clock does not start until a plaintiff knew, or through reasonable diligence should have known, that their injury was caused by the drug.

Before the FDA's January 2022 communication, few patients or physicians connected dental deterioration to Suboxone film. That lack of publicly available causation information supports discovery rule arguments for pre-2022 injury.

Statute of Limitations Factors to Evaluate:

• Date you first used Suboxone film
• Date dental injuries first appeared
• Date you first learned Suboxone could cause dental damage
• Whether your state recognizes the discovery rule for pharmaceutical claims
• Whether any tolling agreement exists between your counsel and the defendants
• Whether a long-term latency argument applies given the cumulative nature of enamel erosion

*Attorneys handling these claims point to tolling agreements as a practical protection that mass tort defense counsel sometimes negotiates early in an MDL to avoid a flood of statute of limitations disputes that slow case management.*

How to File a Suboxone Lawsuit

Filing a Suboxone lawsuit in 2026 means retaining a mass tort attorney who handles pharmaceutical product liability cases and who can evaluate your prescription history, dental records, and state-specific deadline issues before filing.

The process follows the standard MDL plaintiff pathway. Your attorney files a complaint in federal court. The case is then transferred to MDL 3092 in the Northern District of Ohio before Judge David A. Ruiz through a short form complaint process. You do not file directly in Ohio on your own.

The Filing Process, Step by Step:

Attorneys handling mass torts typically work on contingency. You pay no upfront fees. The attorney collects a percentage of any recovery, usually 33% to 40%, set at the time of retention.

*Attorneys handling these claims point to the record-gathering phase as the step most commonly delayed by claimants, since dental offices and pharmacies are only required to retain records for a set number of years, and that period can expire.*

Suboxone Antitrust Lawsuit vs. Dental Lawsuit

Two legally distinct Suboxone lawsuits are active in 2026. Most people searching about the Suboxone lawsuit are thinking about the dental injury MDL. But a separate antitrust lawsuit exists and covers a different category of claimants entirely.

The antitrust litigation targets Indivior's alleged conduct in suppressing generic buprenorphine/naloxone competition to maintain Suboxone film's market monopoly at artificially high prices. The dental lawsuit targets the company's failure to warn patients about the physical harm caused by the film.

Side-by-Side Comparison:

A patient could theoretically qualify for both tracks. Physical injury and economic harm are not mutually exclusive. An attorney can assess both avenues simultaneously.

*Attorneys handling these claims point to the antitrust track as an underutilized avenue for patients who paid significant out-of-pocket costs for Suboxone film, even if their dental injuries were relatively minor.*

Litigation Watch: The antitrust and dental injury tracks are separate legal actions with different theories of harm, different plaintiff pools, and different potential recoveries, and claimants may qualify for one or both.

This may also interest you: Shein Lawsuit 2026: Claims, Status and Who Qualifies

Suboxone Manufacturer Indivior Lawsuit

Indivior PLC is the primary defendant in MDL 3092. The company manufactures Suboxone sublingual film and has faced a range of legal actions over the product's history, making the dental injury MDL one of multiple litigation fronts the company has navigated.

Indivior was formerly a division of Reckitt Benckiser Group, which spun off the pharmaceutical operations as a separate public company. Aquestive Therapeutics, which developed the film delivery technology used in Suboxone, is also named as a co-defendant in the dental injury litigation.

Indivior's track record with regulators is relevant background. The company previously settled criminal and civil charges with the U.S. Department of Justice in 2019 for $600 million, related to alleged improper marketing of Suboxone. That settlement concerned a different set of allegations but established a pattern of regulatory and legal conflict over the same product.

Indivior Litigation History Relevant to 2026 Claims:

*Attorneys handling these claims point to the 2019 DOJ settlement as evidence that Indivior has a documented history of prioritizing market position over patient safety obligations, a narrative that plaintiff counsel will present to juries.*

Northern District of Ohio Suboxone MDL

The Northern District of Ohio is the federal venue where all Suboxone film dental injury cases have been consolidated under MDL 3092. Assignment to this district was made by the U.S. Judicial Panel on Multidistrict Litigation in February 2023.

Judge David A. Ruiz, a U.S. District Judge in the Northern District of Ohio, is presiding over MDL 3092. His management of the case includes coordinated discovery schedules, expert witness protocols, motion practice, and ultimately the selection and sequencing of bellwether trials.

The Northern District of Ohio has a track record with complex MDL litigation. Its federal courthouse infrastructure, established MDL case management protocols, and proximity to major plaintiff and defense expert witness pools made it a practical choice for this litigation.

Northern District of Ohio MDL 3092 Key Facts:

Individual plaintiffs do not travel to Ohio or interact directly with the Ohio court. Their cases are managed by their retained attorneys through the MDL short form complaint and discovery process.

*Attorneys handling these claims point to the importance of understanding that joining MDL 3092 does not mean going to trial in Ohio. Most cases resolve before any individual goes to court.*

Frequently Asked Questions

Can I still apply for the Suboxone lawsuit in 2026?

Yes, you can still apply for the Suboxone lawsuit in 2026.

MDL 3092 is active, no global settlement has closed the filing window, and the court has not issued a universal bar date for new claims.

State-specific statutes of limitations apply, so the specific deadline for your claim depends on where you lived and when you discovered the connection between Suboxone film and your dental injuries.

What is the filing deadline for Suboxone dental injury claims?

There is no single universal filing deadline for all Suboxone dental injury claims.

Each claimant's deadline is governed by the personal injury statute of limitations in their state, which ranges from one to six years, measured from when they knew or should have known Suboxone caused their dental harm.

The FDA's January 2022 dental safety communication is a key reference date that courts may use to assess when claimants had constructive notice of the risk.

Does the Suboxone lawsuit cover tablets or only the film?

MDL 3092 covers only the Suboxone sublingual film formulation, not tablets.

The film's dissolution mechanism involves prolonged contact between acidic drug content and oral tissue, which is the alleged cause of enamel erosion and decay.

Suboxone tablets were discontinued by Indivior in 2012 and do not share the same extended oral contact profile that underlies the dental injury claims.

How much can I expect to receive from a Suboxone settlement?

No confirmed global settlement amount exists as of 2026, so no guaranteed per-person figure is available.

Attorney projections based on analogous pharmaceutical MDLs suggest individual payouts ranging from $10,000 for mild injury to $150,000 or more for catastrophic dental damage including multiple tooth loss and reconstruction.

Actual awards depend on injury severity, quality of documentary evidence, and negotiated settlement structures following bellwether trial outcomes.

What evidence do I need to file a Suboxone lawsuit claim?

The core evidence needed includes prescription records confirming Suboxone film use, pharmacy fill records, and dental records from before, during, and after your Suboxone use period.

Records showing the onset of dental injury during your film use, along with receipts or insurance documents for dental treatment, strengthen the causation case.

An attorney will guide the record-gathering process, and most mass tort firms request these materials during an initial free case evaluation.

What is the difference between the Suboxone dental lawsuit and the antitrust lawsuit?

The Suboxone dental lawsuit, MDL 3092, targets Indivior for failing to warn patients that the film causes tooth decay and dental erosion.

The antitrust lawsuit is a separate legal action alleging that Indivior suppressed generic competition to keep Suboxone film prices artificially high, harming patients and payors financially.

A person who used Suboxone film and suffered both dental injuries and economic harm from overpriced prescriptions may have grounds to pursue claims under both tracks.

Where MDL 3092 Stands and What to Do Next

MDL 3092 is active. The filing window remains open. But mass torts move on their own timeline, and the most significant inflection points, bellwether verdicts and global settlement negotiations, create conditions that favor claimants who are already in the litigation.

If you used Suboxone sublingual film and experienced tooth decay, erosion, fractures, or tooth loss, the first concrete step is gathering your prescription and dental records. The second is speaking with an attorney who practices mass tort pharmaceutical litigation.

Attorneys handling claims like these work on contingency. There is no upfront cost to have your eligibility evaluated. The cost of delay, under state statutes of limitations, is the permanent loss of the right to file.

You may want to read Contractor Ronald Lewis Ohio Lawsuit: 2026 Guide